It is impossible to attain zero risk from blood transfusion ... because of non-ABO antibodies, transfusion-associated graft-versus-host disease (TA-GVHD), post-transfusion purpura (PTP) and ...

A novel regimen significantly reduced risk for moderate to severe chronic graft-versus-host disease for certain patients who ...

The incidence of GVHD was significantly ... "important for adults with TDT [transfusion-dependent thalassemia] who are receiving standard treatment with blood transfusions and chelation therapy ...

Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of moderate-to-severe chronic graft versus host disease (GvHD).

In addition, this model provides an opportunity to further elucidate the precise mechanism(s) by which IVIG inhibit GvHD. Human and murine cell populations in peripheral blood samples collected ...

GvHD causes life-threatening immune system ... University Medical Center's Department of Immunohematology and Blood Transfusion in The Netherlands. Fibbe, who was an author on the Lancet paper ...